Management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 279-287 Year: 2010
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 589-596 Year: 2012
Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Source: Eur Respir Rev 2010 19: 272-278 Year: 2010
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management Source: Eur Respir Rev 2010 19: 314-320 Year: 2010
Pulmonary hypertension: diagnosis, differential diagnosis and pitfalls Source: Eur Respir Mon 2012; 57: 17-25 Year: 2012
Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation Source: Eur Respir J 2010; 35: 1079-1087 Year: 2010
Safety related to maximal cardiopulmonary exercise testing in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020
Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014
EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan® Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
The new World Health Organization classification of lung tumours Source: Eur Respir J 2001; 18: 1059-1068 Year: 2001
World Health Organization treatment outcome definitions for tuberculosis: 2021 update Source: Eur Respir J, 58 (2) 2100804; 10.1183/13993003.00804-2021 Year: 2021
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Clinical and haemodynamic predictors of abnormal pulmonary vascular response at exercise Source: International Congress 2015 – Pulmonary hypertension: new pathophysiological insights Year: 2015
Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension Source: Eur Respir J, 51 (2) 1700444; 10.1183/13993003.00444-2017 Year: 2018
World Health Organization classification and risk factors for pulmonary arterial hypertension Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=204 Year: 2004
LATE-BREAKING ABSTRACT: Functional and clinical correlations of daily physical activity in patients with pulmonary arterial hypertension Source: International Congress 2015 – Multidimensional analysis of respiratory problems Year: 2015